RCKT

Rocket Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

3.140

-0.07(-2.181%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.190

Open

3.110

VWAP

3.14

Vol

2.53M

Mkt Cap

338.30M

Low

3.060

Amount

7.93M

EV/EBITDA(TTM)

Total Shares

90.78M

41.38M

EV/OCF(TTM)

P/S(TTM)

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.532

-28.14%

-0.520

-26.78%

-0.510

-17.75%

Estimates Revision

The market is revising Downward the revenue expectations for Rocket Pharmaceuticals, Inc. (RCKT) for FY2025, with the revenue forecasts being adjusted by -75.69% over the past three months. During the same period, the stock price has changed by -56.15%.

Revenue Estimates for FY2025

Revise Downward

-75.69%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.73%

In Past 3 Month

Stock Price

Go Down

-56.15%

In Past 3 Month

18 Analyst Rating

230.25% Upside

Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 10.37 USD with a low forecast of 2.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

7 Hold

1 Sell

Moderate Buy

230.25% Upside

Current: 3.140

Low

2.00

Averages

10.37

High

30.00

230.25% Upside

Current: 3.140

Low

2.00

Averages

10.37

High

30.00

BofA

Buy -> Neutral

downgrade

$9 -> $4

2025-07-25

New

Reason

BofA

Price Target

$9 -> $4

2025-07-25

New

downgrade

Buy -> Neutral

Reason

BofA downgraded Rocket Pharmaceuticals to Neutral from Buy with a price target of $4, down from $9. Given the FDA's clinical hold on RP-A501, the decision to reduce expenses and re-prioritize the pipeline makes "financial and strategic sense," the analyst tells investors. However, the firm also views the decision as "tacit acknowledgement that the outlook for the story's primary value driver and anchor asset is likely to remain uncertain near term," the analyst added. The firm thinks investors may be slow to re-engage, leaving shares range-bound in the near term.

Canaccord

Buy

downgrade

$11 -> $10

2025-07-25

New

Reason

Canaccord

Price Target

$11 -> $10

2025-07-25

New

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Rocket Pharmaceuticals to $10 from $11 and keeps a Buy rating on the shares. The firm said the company's announced pipeline reprioritization to focus on AAV cardio platform and corporate restructuring is the right move as it will reduce operating expenses and extend its cash runway into 2Q27.

UBS

Buy

downgrade

$12 -> $5

2025-06-18

Reason

UBS

Price Target

$12 -> $5

2025-06-18

downgrade

Buy

Reason

UBS lowered the firm's price target on Rocket Pharmaceuticals to $5 from $12 and keeps a Buy rating on the shares. UBS is optimistic on second half of 2025 PKP2 read-out, but is cautiously optimistic on possible recovery of the Danon program as Rocket seems to have isolated the root cause for patient death, the analyst tells investors in a research note.

Canaccord

Whitney Ijem

Buy

downgrade

$34 -> $11

2025-06-03

Reason

Canaccord

Whitney Ijem

Price Target

$34 -> $11

2025-06-03

downgrade

Buy

Reason

Canaccord analyst Whitney Ijem lowered the firm's price target on Rocket Pharmaceuticals to $11 from $34 and keeps a Buy rating on the shares. The firm noted last week's announcement of a clinical hold on lead program RP-A501 for Danon Disease following AEs (adverse event), a protocol adjustment, new AEs and ultimately a patient death. This is a clear setback from a timing and sentiment perspective.

Evercore ISI

Gavin Clark-Gartner

Outperform -> In Line

downgrade

2025-05-30

Reason

Evercore ISI

Gavin Clark-Gartner

Price Target

2025-05-30

downgrade

Outperform -> In Line

Reason

Evercore ISI analyst Gavin Clark-Gartner downgraded Rocket Pharmaceuticals to In Line from Outperform with a $5 price target.

Evercore ISI

Outperform -> In Line

downgrade

$18 -> $5

2025-05-30

Reason

Evercore ISI

Price Target

$18 -> $5

2025-05-30

downgrade

Outperform -> In Line

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Rocket Pharmaceuticals Inc (RCKT.O) is -1.58, compared to its 5-year average forward P/E of -8.44. For a more detailed relative valuation and DCF analysis to assess Rocket Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.44

Current PE

-1.58

Overvalued PE

-3.46

Undervalued PE

-13.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7.50

Current EV/EBITDA

-0.21

Overvalued EV/EBITDA

-2.32

Undervalued EV/EBITDA

-12.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

718.59

Current PS

67.43

Overvalued PS

3155.37

Undervalued PS

-1718.19

Financials

Annual

Quarterly

FY2025Q1

0.00

Total Revenue

FY2025Q1

YoY :

-4.43%

-64.39M

Operating Profit

FY2025Q1

YoY :

-1.16%

-61.33M

Net Income after Tax

FY2025Q1

YoY :

-15.15%

-0.56

EPS - Diluted

FY2025Q1

YoY :

-4.65%

-56.15M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

4.3K

USD

3-6

Months

413.7K

USD

6-9

Months

49.7K

USD

0-12

Months

407.6K

USD

Bought

0-3

0.0

USD

Months

3-6

200.8K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

637.9K

Volume

6-9

Months

559.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.9M

Volume

Months

6-9

6.2M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

4.3K

USD

3-6

Months

413.7K

USD

6-9

Months

49.7K

USD

0-12

Months

407.6K

USD

Bought

0-3

0.0

USD

Months

3-6

200.8K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RCKT News & Events

Events Timeline

2025-07-24 (ET)

2025-07-24

07:26:03

Rocket Pharmaceuticals to reduce workforce by 30%, anticipates program delays

2025-07-17 (ET)

2025-07-17

07:03:13

Rocket Pharmaceuticals receives RMAT designation for RP-A601 from FDA

2025-06-30 (ET)

2025-06-30

07:02:33

Rocket Pharmaceuticals receives FDA clearance of RP-A701

News

9.0

07-25Globenewswire

PinnedFDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

7.0

07-27PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

7.0

07-26PRnewswire

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit